Skip to main
NDRA

NDRA Stock Forecast & Price Target

NDRA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ENDRA Life Sciences Inc. is poised for growth due to its innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology, which addresses a critical gap in the diagnosis and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) affecting over one billion individuals worldwide. The company anticipates potential FDA approval within the next year, a key catalyst that could significantly enhance the stock's value based on net present value (NPV) analysis, indicating substantial upside potential. Furthermore, TAEUS is designed to improve the accuracy and cost-effectiveness of liver disease diagnoses and monitoring compared to existing technologies, positioning the company favorably in the healthcare market.

Bears say

ENDRA Life Sciences Inc reported a net loss of $1.6 million, resulting in an earnings per share (EPS) of $(2.10), which fell short of estimates. The company faces significant risks, including balance sheet and liquidity challenges, potential failures in clinical trials, regulatory approval hurdles, and obstacles in commercialization and reimbursement processes. Additionally, competition and broader macroeconomic factors may negatively impact investor sentiment towards biotech and medtech investments, contributing to a pessimistic outlook on the stock.

NDRA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ENDRA Life Sciences (NDRA) Forecast

Analysts have given NDRA a Strong Buy based on their latest research and market trends.

According to 1 analysts, NDRA has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ENDRA Life Sciences (NDRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.